Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-γ (PPAR-γ)-deficient mice

Diabetologia

Volumn 53, Issue 7, 2010, Pages 1493-1505

  Duan, S Z ^a,b   Usher, M G ^a   Foley, E L ^a,c   Milstone, D S ^d   Brosius III, F C ^a   Mortensen, R M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adipose tissue; Insulin resistance; Macrophage; PPAR ; Rosiglitazone

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; INSULIN SENSITIVITY; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SEX DIFFERENCE; TISSUE GROWTH;

EID: 77955656006     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1748-2     Document Type: Article

References (50)

1. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244-251.
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
3. Burant CF, Sreenan S, Hirano K et al (1997) Troglitazone action is independent of adipose tissue. J Clin Invest 100:2900-2908.
4. Chao L, Marcus-Samuels B, Mason MM et al (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:1221-1228.
5. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82.
6. Schenk S, Saberi M, Olefsky JM (2008) Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 118:2992-3002.
7. Bouhlel MA, Derudas B, Rigamonti E et al (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6:137-143.
8. Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175-184.
9. Kang K, Reilly SM, Karabacak V et al (2008) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7:485-495.
10. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A et al (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7: 496-507.
11. Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. Front Biosci 13:453-461.
12. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
13. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969.
14. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447:1116-1120.
15. Hevener AL, Olefsky JM, Reichart D et al (2007) Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669.
16. He W, Barak Y, Hevener A et al (2003) Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100:15712-15717.
17. Hevener AL, He W, Barak Y et al (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9:1491-1497.
18. Matsusue K, Haluzik M, Lambert G et al (2003) Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111:737-747.
19. Gavrilova O, Haluzik M, Matsusue K et al (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268-34276.
20. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224-1234.
21. Duan SZ, Ivashchenko CY, Whitesall SE et al (2007) Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 117:812-822.
22. Sowell MO, Ye C, Ricupero DA et al (1997) Targeted inactivation of alphai2 or alphai3 disrupts activation of the cardiac muscarinic K+ channel, IK+Ach, in intact cells. Proc Natl Acad Sci U S A 94:7921-7926.
23. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM (2005) Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 97:372-379.
24. Rosen ED, Sarraf P, Troy AE et al (1999) PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617.
25. Saltiel AR (2003) Putting the brakes on insulin signaling. N Engl J Med 349:2560-2562.
26. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI (2000) Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456-8460.
27. Gavrilova O, Marcus-Samuels B, Graham D et al (2000) Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278.
28. Yamauchi T, Kamon J, Waki H et al (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245-41254.
29. Tsuchida A, Yamauchi T, Takekawa S et al (2005) Peroxisome proliferator-activated receptor (PPAR){alpha} activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPAR{alpha}, PPAR {gamma}, and their combination. Diabetes 54:3358-3370.
30. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277-359.
31. Miyazaki Y, Mahankali A, Matsuda M et al (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791.
32. Barak Y, Nelson MC, Ong ES et al (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595.
33. Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289-312.
34. Watanabe M, Inukai K, Katagiri H, Awata T, Oka Y, Katayama S (2003) Regulation of PPAR gamma transcriptional activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 300:429-436.
35. Van Ginderachter JA, Movahedi K, van den Bossche J, de Baetselier P (2008) Macrophages, PPARs, and cancer. PPAR Res 2008:169414.
36. Rosen ED, Kulkarni RN, Sarraf P et al (2003) Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 23:7222-7229.
37. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K (2005) Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 288: E510-E518.
38. Diani AR, Peterson T, Sawada GA et al (1984) Ciglitazone, a new hypoglycaemic agent. 4. Effect on pancreatic islets of C57BL/6J-ob/ob and C57BL/KsJ-db/db mice. Diabetologia 27: 225-234.
39. Anderson LA, McTernan PG, Barnett AH, Kumar S (2001) The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and site. J Clin Endocrinol Metab 86:5045-5051.
40. Adams M, Montague CT, Prins JB et al (1997) Activators of peroxisome proliferator-activated receptor gamma have depotspecific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153.
41. Macotela Y, Boucher J, Tran TT, Kahn CR (2009) Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. Diabetes 58:803-812.
42. de Souza CJ, Eckhardt M, Gagen K et al (2001) Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50:1863-1871.
43. Okuno A, Tamemoto H, Tobe K et al (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361.
44. Fujiwara T, Wada M, Fukuda K et al (1991) Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 40:1213-1218.
45. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406.
46. Kim JK, Fillmore JJ, Gavrilova O et al (2003) Differential effects of rosiglita-zone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 52:1311-1318.
47. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Muller M (2008) Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem 283:22620-22627.
48. Gras D, Chanez P, Urbach V, Vachier I, Godard P, Bonnans C (2009) Thiazolidinediones induce proliferation of human bronchial epithelial cells through the GPR40 receptor. Am J Physiol Lung Cell Mol Physiol 296:L970-L978.
49. Lecomte J, Flament S, Salamone S et al (2008) Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines. Breast Cancer Res Treat 112:437-451.
50. Colca JR, McDonald WG, Waldon DJ et al (2004) Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286:E252-E260.